MARKET

EVOK

EVOK

Evoke Pharma Inc
NASDAQ
0.5100
-0.0301
-5.57%
Closed 15:17 04/12 EDT
OPEN
0.5374
PREV CLOSE
0.5401
HIGH
0.5399
LOW
0.5000
VOLUME
32.59K
TURNOVER
0
52 WEEK HIGH
2.420
52 WEEK LOW
0.5000
MARKET CAP
4.32M
P/E (TTM)
-0.2188
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EVOK last week (0401-0405)?
Weekly Report · 6d ago
Weekly Report: what happened at EVOK last week (0325-0329)?
Weekly Report · 04/01 11:50
Weekly Report: what happened at EVOK last week (0318-0322)?
Weekly Report · 03/25 11:53
Evoke Pharma Welcomes Matthew D’Onofrio as New CEO
TipRanks · 03/21 20:33
Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer
Evoke Pharma taps Matthew D'Onofrio to succeed David Gonyer as chief executive. The company says he is departing for personal reasons. D' onofrio will assume Gonye's board seat on March 31, effective March 31. The specialty pharmaceutical company is called Evoke Pharma.
Dow Jones · 03/21 20:25
Evoke Pharma names Matthew D’Onofrio as new CEO
Seeking Alpha · 03/21 20:21
*Evoke Pharma: D'Onofrio Will Assume Gonyer's Board Seat as of March 31 >EVOK
Dow Jones · 03/21 20:18
*Evoke Pharma: Gonyer's Departure Is for Personal Reasons >EVOK
Dow Jones · 03/21 20:17
More
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Webull offers Evoke Pharma Inc stock information, including NASDAQ: EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.